Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
165,974,436
-
Total 13F shares
-
57,306,752
-
Share change
-
-2,104,910
-
Total reported value
-
$89,403,802
-
Put/Call ratio
-
17%
-
Price per share
-
$1.56
-
Number of holders
-
97
-
Value change
-
-$3,332,109
-
Number of buys
-
37
-
Number of sells
-
37
Institutional Holders of Xeris Biopharma Holdings, Inc. - Common Stock (XERS) as of Q3 2022
As of 30 Sep 2022,
Xeris Biopharma Holdings, Inc. - Common Stock (XERS) was held by
97 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
57,306,752 shares.
The largest 10 holders included
Stonepine Capital Management, LLC, BlackRock Inc., VANGUARD GROUP INC, CAXTON CORP, NEA Management Company, LLC, ARMISTICE CAPITAL, LLC, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, Invesco Ltd., and NORTHERN TRUST CORP.
This page lists
97
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.